Quince Therapeutics (QNCX) Treasury Shares (2018 - 2025)

Quince Therapeutics (QNCX) posted quarterly Treasury Shares of $5408.0 for Q3 2025, down 81.82% quarter-over-quarter from $29745.0 in Q2 2025.

Quince Therapeutics (QNCX) Treasury Shares (2018 - 2025) Analysis & Trends

Quince Therapeutics' Treasury Shares history runs 6 years deep, the most recent figure standing at $5408.0 for Q3 2025.

In Q3 2025, Treasury Shares changed N/A year-over-year to $5408.0; the TTM figure through Sep 2025 stood at $5408.0 (changed N/A YoY), while the FY2024 annual figure was $78417.0, down 55.39% from the prior year.
Treasury Shares for Q3 2025 stood at $5408.0, down from $29745.0 in the prior quarter.
The five-year high for Treasury Shares was $1.0 million in Q1 2022, with the low at $5408.0 in Q3 2025.
The 4-year median for Treasury Shares is $187931.0 (2023), against an average of $285247.0.
The sharpest annual moves came in 2023 and 2025: Treasury Shares sank 35.9% in 2023, then plunged 76.6% in 2025.
Quince Therapeutics' Treasury Shares stood at $427401.0 in 2022, then tumbled by 58.88% to $175763.0 in 2023, then plunged by 55.38% to $78417.0 in 2024, then tumbled by 93.1% to $5408.0 in 2025.
Business Quant data shows QNCX's Treasury Shares at $5408.0 in Q3 2025, $29745.0 in Q2 2025, and $54081.0 in Q1 2025.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Treasury Shares (Qtr)
1	Vertex Pharmaceuticals	139.13 Bn	131.28 Bn	2.84 Bn	-
2	Regeneron Pharmaceuticals	85.77 Bn	77.77 Bn	3.93 Bn	36.40 Mn
3	Argenx Se	64.64 Bn	59.46 Bn	1.37 Bn	-
4	Moderna	58.29 Bn	53.16 Bn	52.00 Mn	-
5	BeOne Medicines	41.92 Bn	36.82 Bn	1.53 Bn	-
6	Alnylam Pharmaceuticals	31.58 Bn	28.28 Bn	992.69 Mn	-
7	BioNTech SE	28.12 Bn	9.73 Bn	668.28 Mn	8.96 Mn
8	Insmed	27.39 Bn	26.22 Bn	358.27 Mn	-
9	Royalty Pharma	27.27 Bn	26.43 Bn	-	2.72 Mn
10	Quince Therapeutics	203.43 Mn	203.43 Mn	-	211,301.87

Download Data